← Back to headlines
Corcept Therapeutics Shares Surge on FDA Nod for Ovarian Cancer Drug
Corcept Therapeutics shares surged after its lead drug received approval from the FDA for the treatment of ovarian cancer, marking a significant milestone for the company.
25 Mar, 17:18 — 25 Mar, 17:18
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (32/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left1
Left (1)
Yahoo
Center1
Center (1)
Reuters
Right
Far R
Geographic diversity— 2 regions9/34
Intl1US1
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
ReutersVery High16d ago
Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer - Reuters
Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer Reuters
Read full article →YahooMostly Factual16d ago
Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer
Read full article →Coverage Timeline
First report: Yahoo · 25 Mar, 17:18|Full coverage: 2 · 0m|Window: 0m
Left-leaningCenterRight-leaning
